Hamostaseologie 2019; 39(S 01): S1-S92
DOI: 10.1055/s-0039-1680206
DOI: 10.1055/s-0039-1680206
Poster
P06 TTP; HUS
Risk Factors and Manageability of the Mucocutaneous Bleeding Profile Observed in aTTP Patients Treated with Caplacizumab during the Phase III HERCULES Study
Authors
-
S. Cataland
1 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States -
M. Scully
2 Department of Hematology, University College London Hospitals NHS Trust, London, United Kingdom -
F. Peyvandi
3 University of Milan/Fondazione IRCCS Ca´ Grande Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy -
P. Coppo
4 Department of Hematology, Saint-Antoine University Hospital, Paris, France -
P. Knoebl
5 Division of Hematology and Hemostasis, Department of Medicine 1, University Hospital, Wien, Austria -
J.A. Hovinga Kremer
6 Clinic of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland -
A. Metjian
7 Division of Hematology, Duke University School of Medicine, Durham, North Carolina, United States -
J. de la Rubia
8 Department of Hematology, Universidad Católica de Valencia Hospital Doctor Peset, Valencia, Spain -
K. Pavenski
9 Department of Laboratory Medicine and Pathobiology, Research Institute, St Michael´s Hospital, Toronto, Ontario, Canada -
J. Minkue
10 Ablynx NV, Zwijnaarde, Belgium -
R. Sousa
10 Ablynx NV, Zwijnaarde, Belgium -
F. Callewaert
10 Ablynx NV, Zwijnaarde, Belgium -
H. de Winter
10 Ablynx NV, Zwijnaarde, Belgium
